Pfizer's Abrocitinib Looks Competitive In Atopic Dermatitis

 
• By Mandy Jackson

The first detailed Phase III results for the company's next-generation oral JAK inhibitor abrocitinib appear to show efficacy on par or better than data from Sanofi/Regeneron's Dupixent and may give Lilly's Olumiant a run for its money in AD.

Women scratch the itch with hand , Concept with Healthcare And Medicine. - Image
Abrocitinib appears to rapidly reduce itching, a hallmark of AD. • Source: Shutterstock

More from Clinical Trials

More from R&D